Medgenics, Inc. MDGN, the
developer of Biopump^TM a novel technology for the sustained production and
delivery of therapeutic proteins in patients using their own tissue, today
announced a patent granted by the U.S. Patent and Trademark Office (USPTO)
protecting the use of Medgenics' EPODURE Biopump technology for delivery of
erythropoietin (EPO). Medgenics is developing EPODURE to address the need for
safer, sustained treatment of anemia. The USPTO also allowed claims covering a
similar method for delivery of clotting Factor VIII, underlying Medgenics'
HEMODURE™ Biopump technology for sustained prophylactic treatment of
hemophilia.
Similar claims covering EPODURE and HEMODURE have also been recently allowed
in Japan, China, Korea and Australia.
In total, Medgenics' global portfolio now includes 36 patents issued, with 81
more pending.
Medgenics believes its approach to protein therapy has multiple benefits
compared with current treatments, which include regular and costly injections
of therapeutic proteins. Medgenics' technologies target the global protein
therapy market which is forecast to reach $132 billion in 2013.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in